Mergers and Acquisitions

(Image: Getty/Robert Daly)

UCB set to buy Ra Pharma for $2.1bn

By Ben Hargreaves

With both boards of directors in agreement, UCB is on track to add the clinical stage biopharma company and its lead drug candidate, zilucoplan, to its portfolio.

Follow us

Products

View more

Webinars